Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna's headquarters in Cambridge, Mass., in 2024. (dam Glanzman / Bloomberg via Getty Images) (Adam Glanzman) The Food and Drug ...

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day. This change lagged the S&P 500's daily loss of 1.51%. On the other hand, the Dow registered ...

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today’s Market Action. Moderna snapped a two-day losing streak ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Update: The FDA reversed its decision on Feb. 18 and agreed to consider Moderna's application. Read the latest here. Our earlier story is below. The Food and Drug Administration is refusing to ...

The Food and Drug Administration reversed course on Wednesday and agreed to formally review Moderna’s new flu vaccine that uses mRNA technology, the company announced in a news release. Earlier this ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.The news is the ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.